93. 原発性胆汁性胆管炎 Primary biliary cholangitis Clinical trials / Disease details
|1||JPRN-UMIN000012193||2013/11/01||01/11/2013||Efficacy of the anti-RANKL human antibody (Denosumab) versus Bisphosphonate for the treatment of osteoporosis in patients with primary biliary cirrhosis||Efficacy of the anti-RANKL human antibody (Denosumab) versus Bisphosphonate for the treatment of osteoporosis in patients with primary biliary cirrhosis - Denosumab versus Bisphosphonate for osteoporosis in patients with PBC||Osteoporosis in biopsy-proven primary biliary cirrhosis patients pretreated with bisphosphonate||Discontinue the administration of aredoron acid, risedronic acid, and minodronic acid. Then, 60mg of denosumab will be subcutaneously injected every 6 months for 12 months. All patients will take activated vitamin D. In the case of hypocalcemia, calcium will be administrated appropriately.|
Continue the administration of bisphosphonate as heretofore. All patients will take activated vitamin D.
|Juntendo University School of Medicine||NULL||Complete: follow-up complete||20years-old||Not applicable||Male and Female||60||Not applicable||Japan|